Figure 4

LK63 and Reh xenograft were treated with vehicle or cIIIA4 mAb. (a) Reduced spleen engraftment in LK63 xenograft at 30, 100, 250 and 1000 μg of cIIIA4 compared with vehicle treatment (P<0.0001). No significant difference between 100, 250 and 1000 μg cIIIA4 dosing (n⩾4). (b) Percentage of bone marrow engraftment in LK63 xenografts in response to PBS, IgG-control and cIIIA4 at 100 μg (n=8). (c) Reduced splenic engraftment in 100 μg cIIIA4-treated LK63 xenografts compared with PBS and IgG-control treatment (P<0.0002, n=8). (d) Significant reduction in cIIIA4-treated LK63 xenograft spleen weight (P=0.0006) and engraftment (P<0.0001) compared with PBS. There were no significant reduction in bone marrow engraftment (n=16 PBS, n=17 IIIA4, four experiments). (e) Representative Xenogen images of LK63 xenografts day 9, 14, 18 and 22. (f) No differences in spleen weight, spleen and bone marrow engraftments of Reh xenografts treated with cIIIA4 or PBS (n=15, three experiments). (g) Representative Xenogen images of Reh xenografts days 14, 18, 25 and 29. Point in graphs (d) and (e) corresponds to one mouse. Data presented as mean percentage±s.e.m. Unpaired t-tests or one-way analysis of variance (ANOVA) performed for statistical analyses.